Market Research Logo

Cardiomyopathy - Pipeline Review, H2 2015

Cardiomyopathy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Cardiomyopathy - Pipeline Review, H2 2015’, provides an overview of the Cardiomyopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Cardiomyopathy Overview
Therapeutics Development
Pipeline Products for Cardiomyopathy - Overview
Pipeline Products for Cardiomyopathy - Comparative Analysis
Cardiomyopathy - Therapeutics under Development by Companies
Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes
Cardiomyopathy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cardiomyopathy - Products under Development by Companies
Cardiomyopathy - Products under Investigation by Universities/Institutes
Cardiomyopathy - Companies Involved in Therapeutics Development
Array BioPharma Inc.
Bioheart, Inc.
Gilead Sciences, Inc.
Heart Metabolics Limited
Hemostemix Ltd
Kasiak Research Private Limited
miRagen Therapeutics, Inc.
MyoKardia, Inc.
Neurimmune Holding AG
Nyken BV
Sanofi
Shire Plc
Stemedica Cell Technologies, Inc.
Stempeutics Research Private Limited
Torrent Pharmaceuticals Limited
Vericel Corporation
Virocan Therapeutics Private Limited
Cardiomyopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AdipoCell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AmVidcm-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-797 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eleclazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Cardiomyopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixmyelocel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JR-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-9103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MYK-461 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NI-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYK-1112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
perhexiline maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Peptide to Agonize GLP-1 for Cardiomyopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refacell-DCM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-627 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stempeucel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRC-120038 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YS-1402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiomyopathy - Recent Pipeline Updates
Cardiomyopathy - Dormant Projects
Cardiomyopathy - Dormant Projects
Cardiomyopathy - Discontinued Products
Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy
Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy
Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cardiomyopathy, H2 2015
Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2015
Cardiomyopathy - Pipeline by Bioheart, Inc., H2 2015
Cardiomyopathy - Pipeline by Gilead Sciences, Inc., H2 2015
Cardiomyopathy - Pipeline by Heart Metabolics Limited, H2 2015
Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2015
Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2015
Cardiomyopathy - Pipeline by miRagen Therapeutics, Inc., H2 2015
Cardiomyopathy - Pipeline by MyoKardia, Inc., H2 2015
Cardiomyopathy - Pipeline by Neurimmune Holding AG, H2 2015
Cardiomyopathy - Pipeline by Nyken BV, H2 2015
Cardiomyopathy - Pipeline by Sanofi, H2 2015
Cardiomyopathy - Pipeline by Shire Plc, H2 2015
Cardiomyopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Cardiomyopathy - Pipeline by Stempeutics Research Private Limited, H2 2015
Cardiomyopathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
Cardiomyopathy - Pipeline by Vericel Corporation, H2 2015
Cardiomyopathy - Pipeline by Virocan Therapeutics Private Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2015
Cardiomyopathy - Dormant Projects, H2 2015
Cardiomyopathy - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Cardiomyopathy, H2 2015
Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report